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Abstract 
Differential regulation of the µ-opioid receptor (MOPr) contributes to the clinically limiting effects of opioid 
analgesics, such as morphine. However, whether differential regulation of MOPr impacts on the spatiotemporal 
characteristics of receptor activation is unclear. Here we used biophysical approaches to quantify MOPr 
spatiotemporal signaling. Morphine caused a Gbg-dependent increase in membrane-localized PKC activity, 
which restricted the distribution of MOPr within the plasma membrane and induced sustained cytosolic 
extracellular signal-regulated kinase (ERK). In contrast, DAMGO ([D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin) 
allowed receptor redistribution, transient increases in cytosolic and nuclear ERK, and then receptor 
internalization. Following inhibition of Gbg-subunits, PKCa or mutation of a key phosphorylation site, the 
morphine-activated MOPr is released from its restricted localization and stimulates a transient increase in 
cytosolic and nuclear ERK in the absence of b-arrestin recruitment and internalization. Thus, ligand-induced 
redistribution of MOPr at the plasma membrane, and not internalization, controls its spatiotemporal signaling.  
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Introduction 
G protein-coupled receptors (GPCRs) are the largest family of cell surface signaling proteins encoded by the 
human genome. They allow cells to respond to structurally diverse endogenous and environmental signals, and 
are the target of over 30% of marketed drugs. It is increasingly recognized that the uniform elevation of second 
messengers throughout the cell cannot explain the diversity of GPCR-mediated effects. Rather, spatial (location) 
and temporal (duration) control of signaling plays an important role (1, 2). Spatial compartmentalization of 
signaling can be achieved by the formation of GPCR-dependent protein complexes, which ultimately restrict 
second messenger diffusion to induce extremely localized signals (3). In addition, multiple regulatory 
mechanisms (including receptor phosphorylation, desensitization and internalization) control the duration of 
GPCR activation. Therefore, the spatial and temporal distribution of both receptors and signaling effectors are 
critical for the generation of distinct and highly specialized GPCR-mediated responses. 
 
The  µ-opioid receptor (MOPr) has been extensively studied due to its physiological importance in mediating the 
effects of endogenous opioids, and its prominence as the target of opioid analgesics, such as morphine. Despite 
this, chronic use of opioid analgesics is still clinically limited by the development of tolerance, addiction, 
constipation and respiratory depression (4). At a cellular level, stimulation of MOPr by all opioids activates the 
same G protein-dependent signaling pathways. MOPr activates Gai/o proteins leading to an inhibition of cAMP, 
increased ERK phosphorylation, activation of G protein-regulated inwardly rectifying potassium channels, and 
inhibition of voltage-gated calcium channels (5). However, different MOPr agonists induce distinct patterns of 
receptor regulation and internalization. In particular, morphine causes limited receptor phosphorylation and b-
arrestin recruitment, which results in compromised receptor internalization and resensitization (6-10). These 
observations have prompted intensive studies of the ability of MOPr ligands to differentially activate G proteins 
and b-arrestins, in an effort to explain their divergent biological effects (11-13). 
 
It is now apparent that the spatiotemporal characteristics of a signal can specify the outcome of receptor 
activation (1, 2). Most opioids, including morphine, elicit cytosolic ERK phosphorylation (14-16). However, 
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unlike other opioids, morphine is unable to promote nuclear ERK phosphorylation (15). Taken together with its 
impaired internalization of MOPr, this suggests that morphine may stimulate a unique spatiotemporal cellular 
response. To investigate this, we used complimentary biophysical techniques and super-resolution microscopy. 
We report that morphine and DAMGO activate distinct spatial and temporal signaling profiles that are controlled 
by the plasma membrane localization of MOPr induced by the two ligands. Subcellular-targeted Förster 
Resonance Energy Transfer (FRET) biosensors showed that only morphine stimulation of MOPr induced 
sustained cytosolic ERK and plasma membrane-localized PKC activation, which restricted MOPr localization. In 
contrast, DAMGO caused MOPr redistribution within the plasma membrane and transient activation of cytosolic 
and nuclear ERK. Thus, not only do morphine and DAMGO stimulate different signaling pathways, they 
activate signals in distinct subcellular compartments with unique temporal profiles. Importantly, we can alter the 
spatiotemporal signaling profile of morphine to mimic that of DAMGO, by allowing redistribution of MOPr 
within the plasma membrane in the absence of b-arrestin recruitment or receptor internalization. Thus, receptor 
localization within the plasma membrane determines the spatiotemporal signals activated by MOPr in response 
to different ligands.  
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Results 
Ligand-dependent spatiotemporal signaling of MOPr 
To gain spatial and temporal resolution of MOPr signaling in live cells, we used FRET biosensors for ERK and 
PKC (EKAR and CKAR, respectively) localized to different subcellular compartments (17, 18). In HEK293 
cells co-transfected with MOPr and either a cytosolic or nuclear ERK biosensor (cytoEKAR, nucEKAR), EC50 
concentrations of DAMGO (10 nM) or morphine (100 nM; fig. S1A) caused distinct temporal ERK profiles. 
DAMGO caused a transient increase in cytosolic ERK, whereas morphine induced a sustained increase (Fig. 1, 
A and B). Moreover, only DAMGO caused a transient increase in nuclear ERK (Fig. 1, C and D). Ligand-
dependent responses were also observed when assessing direct activation of PKC. In cells co-transfected with 
MOPr and a plasma membrane PKC biosensor (pmCKAR) only morphine caused a sustained increase in PKC 
activity (Fig. 1E). DAMGO did not affect plasma membrane PKC activity, even at maximal concentrations (1 
µM; fig. S1B), and neither ligand affected cytosolic PKC (Fig. 1F). 
 
The distinct internalization profiles of MOPr in response to DAMGO and morphine (6, 10), were quantified 
using a Bioluminescence Resonance Energy Transfer (BRET) assay that detects the proximity between BRET 
partners in defined subcellular compartments in live cells (19, 20). In agreement with previous reports, 
incubation with DAMGO (1 µM, fig. S2A) induced MOPr internalization as shown by the increase in the BRET 
signal between a Renilla luciferase-tagged MOPr (MOPr-RLuc) and a Venus-tagged marker of early endosomes 
(Rab5a-Venus) (Fig. 2A). In contrast, morphine produced no detectable change in BRET (Fig. 2A and fig. S2B). 
These results were validated by automated, high-content image analysis (fig. S2C). DAMGO-mediated MOPr 
endocytosis was unaffected by Gai/o inhibition using NF023 or pertussis toxin (PTx) (21, 22) but was abolished 
by the clathrin-dependent endocytosis inhibitor PitStop2 (23), expression of a dominant negative dynamin 
(K44E) (24) or by knockdown of b-arrestins (combined b-arrestin-1 and b-arrestin-2 siRNA; Fig. 2, A and B 
and fig. S2, D to H). This shows that b-arrestin recruitment and MOPr endocytosis are independent of Gai/o 
coupling.  
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Previous studies have linked activation of PKC to cytosolic ERK, and b-arrestin to increased nuclear ERK, to 
conclude that G protein- and b-arrestin-dependent pathways activate distinct ERK signaling (15). By inhibiting 
Gai/o proteins, we now directly demonstrate that cytosolic ERK in response to DAMGO and morphine is 
dependent on Gai/o (Fig. 2C). In agreement with previous studies, cytosolic ERK was unaffected by knockdown 
of b-arrestins (Fig. 2C). However, inhibition of receptor endocytosis by PitStop2 or dynamin K44E transformed 
the profile of DAMGO-induced cytosolic ERK from a transient to a sustained signal, consistent with MOPr 
retention at the plasma membrane (Fig. 2D and fig. S2, I and J). As expected, the increase in nuclear ERK in 
response to DAMGO was dependent on b-arrestins and receptor internalization (Fig. 2, E and F). 
 
Thus, our results show that Gai/o activation by MOPr mediates increases in cytosolic ERK in response to 
DAMGO and morphine, and confirm that the increases in nuclear ERK in response to DAMGO are dependent 
on b-arrestins and receptor endocytosis. 
 
PKC activation controls the ERK spatiotemporal profile of morphine  
Inhibition of Gai/o (NF023 or PTx) or Gbg-subunits (mSIRK or expression of bARKct) (25, 26) abolished the 
plasma membrane PKC response to morphine (Fig. 3A). There was no effect of knockdown of b-arrestins, or 
negative controls (inactive mSIRK L9A, scrambled siRNA; Fig. 3A and fig. S3A). Thus, the sustained increase 
in plasma membrane PKC induced by morphine is mediated by Gai/o-Gbg. 
 
Previous studies have reported that PKC activity mediates increased cytosolic ERK in response to morphine 
(15). We therefore investigated whether the Gai/o-Gbg-PKC pathway influences the unique ERK spatiotemporal 
signaling profiles of MOPr. Rather than decreasing ERK, and in contrast to previous reports, inhibition of Gbg-
subunits or PKC (GF109203X, Gö6983) (27, 28) transformed the temporal profile of morphine-stimulated 
cytosolic ERK to resemble the transient response induced by DAMGO (Fig. 3B and fig. S3B). Moreover, 
inhibition of the Gbg-PKC pathway also allowed morphine to increase nuclear ERK (Fig. 3, C and D). Previous 
studies have implicated PKCa, PKCg and PKCe as the isoforms that contribute to morphine signaling and to the 
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development of morphine tolerance (16, 29-32). Of these, only PKCa and PKCe are expressed in our HEK293 
cell line (Fig. S3D). Inhibition of PKCa (Gö6976: targets PKCa and PKCb1) (33) but not PKCe (iPKCe peptide, 
a cell-permeable PKCe-inhibitory peptide) (34) transformed the temporal profile of morphine-stimulated 
cytosolic ERK and facilitated an increase in nuclear ERK (fig. S3, E and F). There was no effect of inactive 
controls or of these inhibitors on the response to DAMGO (Fig. 3, B to D and fig. S3, C and F). 
 
As expected, inhibition of Gbg-subunits or PKC had no effect on b-arrestin-2 recruitment or MOPr 
internalization induced by DAMGO, determined by BRET or high-content imaging (Fig. 3E and fig. S3, G to I). 
In contrast, upon inhibition of Gbg-subunits or PKC, morphine activation of MOPr resulted in a decrease in 
BRET between MOPr-RLuc and the plasma membrane marker KRas-Venus (Fig. 3F) suggesting an increase in 
the distance between these two proteins. In the absence of MOPr internalization (Fig. 3E and fig. S3, G to H), 
the morphine-stimulated change in MOPr-KRas BRET may indicate a movement of the receptor away from 
KRas within the plasma membrane. Thus, the transient activation of cytosolic and nuclear ERK elicited by 
morphine does not require MOPr internalization but may instead depend on MOPr translocation within the 
plasma membrane. 
 
The importance of MOPr localization within the plasma membrane for the control of spatiotemporal signaling 
was also supported by the effects observed upon expression of a phosphorylation-impaired MOPr mutant 
(S375A) (35). MOPr S375A still recruited b-arrestin-2 in response to DAMGO, but was unable to internalize as 
determined by high-content imaging or Rab5a BRET (Fig. 3, G and H and fig. S3, G and H). There was no 
change in MOPr S375A-KRas BRET in response to DAMGO or morphine (fig. S3J). However, stimulation of 
MOPr S375A by both DAMGO and morphine induced transient increases in cytosolic and nuclear ERK (Fig. 3I 
and fig. S3K). To confirm that receptor phosphorylation was key for the control of MOPr plasma membrane 
localization and spatiotemporal signaling, we used a phosphorylation-deficient MOPr mutant in which all the C-
terminal Ser and Thr residues have been mutated to Ala (11ST/A) (9). Consistent with previous reports, MOPr 
11ST/A was unable to internalize as determined by Rab5a BRET, or recruit b-arrestin-2 in response to DAMGO 
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(Fig. 3, G and H). However, stimulation of MOPr 11ST/A by both DAMGO and morphine induced a transient 
increase in nuclear ERK, with no change in KRas BRET (Fig. 3I and fig. S3J). Phosphorylation of Ser375 
therefore appears critical for the control of MOPr spatiotemporal signaling in response to morphine. Taken 
together, these data show that the impaired trafficking of MOPr mutants results in an altered signaling profile and 
support the hypothesis that the plasma membrane localization of MOPr, and not b-arrestin recruitment or 
receptor internalization, plays a key role in the spatiotemporal control of receptor signaling. 
 
Ligand-dependent redistribution of MOPr within the plasma membrane 
To investigate the changes in MOPr distribution elicited by morphine upon inhibition of the Gbg-PKCa 
pathway, we assessed receptor localization at the plasma membrane by confocal microscopy and subcellular 
fractionation. After 10 min stimulation of MOPr (which causes activation of all signaling pathways) there was 
no colocalization between the receptor and immunolabeled clathrin by confocal microscopy under any condition 
tested (fig. S4, A and B). However, after 60 min, stimulation with DAMGO but not morphine caused significant 
colocalization between MOPr and clathrin (fig. S4C). In contrast, activation of the fast internalizing b2-
adrenoceptor (b2AR) by isoprenaline caused significant receptor-clathrin colocalization after 10 min (fig. S4, A 
to C). Similarly, there was no effect of DAMGO or morphine stimulation on the location of FLAG-MOPr within 
non-lipid-rich (Triton X-100 soluble) plasma membrane domains using basic lipid fractionation (fig. S4D). 
Therefore, the distinct spatiotemporal signaling profiles of morphine and DAMGO do not reflect ligand-
dependent MOPr clustering in clathrin-coated pits nor translocation to different lipid domains. 
 
To investigate MOPr localization within the plasma membrane with increased resolution, we used ground state 
depletion (GSD) super-resolution microscopy in total internal reflection fluorescence (TIRF) mode. GSD/TIRF 
allows the detection of events within the plane of the plasma membrane to an axial resolution of 100 nm. This 
approach can measure the distance between an event (receptor or receptor clusters) and its nearest neighbor 
across a population. Stimulation of FLAG-MOPr with DAMGO (10 min) increased the average distance 
between detected events (Fig. 4, A and B), suggesting MOPr redistribution within the plasma membrane. This 
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increase in distance occurs prior to and is independent of receptor internalization, as there was no effect of 
expression of dominant negative dynamin K44E (fig. S4, E and F). 
 
Morphine stimulation of FLAG-MOPr (10 min) did not change the average distance between events (Fig. 4, A 
and B). However, following inhibition of Gbg-subunits morphine increased the distance between detected MOPr 
events (Fig. 4, C and D and fig. S4, E and G), suggesting that activation of this pathway by morphine normally 
restricts MOPr localization. Interestingly, the distance between MOPr events under basal conditions following 
expression of MOPr S375A was also increased when compared to the wild-type receptor (Fig. 4, E and F). This 
increase in distance between events was not due to decreased receptor expression at the plasma membrane 
(MOPr S375A 570,000 sites per cell, MOPr wild-type 140,000 sites per cell measured by whole cell [3H]-
diprenorphine binding), confirming that MOPr S375A was differentially distributed compared to the wild-type 
receptor. 
 
Thus, our results suggest that activation of MOPr by morphine restricts receptor localization, whereas DAMGO 
stimulation allows MOPr redistribution within the plasma membrane. Disruption of the Gbg-PKCa-
phosphorylation pathway allows morphine to stimulate a DAMGO-like redistribution of MOPr but does not 
result in receptor internalization. This receptor redistribution precedes (DAMGO), or can occur independently of 
(morphine), endocytosis and appears to control the ability of MOPr to transiently activate cytosolic and nuclear 
ERK. 
 
Disruption of plasma membrane organization alters MOPr spatiotemporal signaling 
To confirm the importance of membrane organization in the control of compartmentalized MOPr signaling, we 
depleted cholesterol from the plasma membrane using methyl-b-cyclodextrin (MbCD) (36) or Filipin III (37). 
There was no effect of these treatments on MOPr internalization, as determined by high-content imaging (fig. 
S5, A and B). However, both MbCD and Filipin III abolished the distinct spatiotemporal signaling profiles of 
morphine and DAMGO (Fig. 5 and fig. S5). Upon cholesterol depletion, both morphine and DAMGO increased 
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PKC activity at the plasma membrane and caused a transient increase in cytosolic and nuclear ERK (Fig. 5 and 
fig. S5, C to F). Importantly, membrane cholesterol replenishment by incubation of the cells with 
MbCD/cholesterol complexes, completely restored the original spatiotemporal signaling profiles of DAMGO 
and morphine (Fig. 5 and fig. S5). 
 
Thus, disruption of membrane organization alters the spatiotemporal signaling profiles of MOPr, with no change 
in the ability of the receptor to internalize, confirming that plasma membrane localization of MOPr plays an 
important role in determining its spatiotemporal signaling. 
 
MOPr compartmentalized signaling in dorsal root ganglia (DRG) neurons 
To confirm the physiological relevance of the spatiotemporal signaling patterns of MOPr when expressed in 
HEK293 cells, we nucleofected isolated neurons from mouse DRG with the FRET biosensors. DRG neurons are 
the principal mediators of nociception from the periphery to the spinal cord and activation of endogenous MOPr 
in these neurons partially mediates the analgesic actions of opioids (38). 
 
Activation of MOPr in DRG neurons stimulated ERK and PKC activity with spatiotemporal profiles that were 
identical to those observed in HEK293 cells. DAMGO caused a transient increase in both cytosolic and nuclear 
ERK, whereas morphine elicited a sustained increase in cytosolic ERK and plasma membrane PKC (Fig. 6, A to 
C). Inhibition of PKC decreased the percentage of neurons that exhibited a sustained cytosolic ERK response to 
morphine (from 75% to 49%), and increased the percentage of neurons that exhibited a transient cytosolic ERK 
response (from 25% to 51%) (Fig. 6, D and E). There was no effect of PKC inhibition on the temporal profile of 
cytosolic ERK following stimulation with DAMGO (Fig. 6, D and E). As observed in HEK293 cells, inhibition 
of PKC allowed morphine to activate nuclear ERK (Fig. 6F). 
 
We also assessed the distribution of endogenous MOPr at the plasma membrane of DRG neurons (Fig. 6G) using 
GSD/TIRF microscopy. As in HEK293 cells, stimulation of endogenous MOPr in DRG neurons with DAMGO 
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increased the distance between detected events at the plasma membrane (Fig. 6, H and I). In contrast, there was 
no change in the distance between MOPr events in response to morphine. 
 
Thus, in DRG neurons, as in HEK293 cells, receptor redistribution at the plasma membrane correlates with 
transient increases in cytosolic and nuclear ERK in response to DAMGO. Moreover, inhibition of PKC allows 
morphine to cause transient increases in cytosolic and nuclear ERK. As such, the spatiotemporal regulation of 
MOPr activation and signaling identified in recombinant expression systems also occurs in DRG neurons 
endogenously expressing this receptor.  
12 
Discussion 
The use of biophysical approaches to assess MOPr signaling in real time and in live cells has revealed a new 
mechanism that contributes to the control of differential MOPr activation. Here we show that DAMGO 
activation of MOPr triggers receptor translocation within the plasma membrane. This translocation precedes 
receptor trafficking to clathrin-containing domains and internalization and is likely dependent on receptor 
phosphorylation (Fig. 7A). This MOPr translocation, not receptor internalization, determines the transient 
cytosolic ERK profile and the activation of nuclear ERK (Fig. 7A). In contrast, morphine activates plasma 
membrane-localized PKCa, via Gbg-subunits, which prevents receptor translocation within the plasma 
membrane. This results in sustained cytosolic ERK and no nuclear ERK activity (Fig. 7B). Inhibition of this 
Gbg-PKCa-phosphorylation pathway allows the morphine-activated MOPr to translocate within the plasma 
membrane and transforms its spatiotemporal signaling profile (Fig. 7B). Importantly, this new signaling profile 
mimics that of the internalizing ligand DAMGO (i.e. transient cytosolic and nuclear ERK) but occurs in the 
absence of b-arrestin-2 recruitment and without receptor internalization.  
 
These results add essential detail to previous descriptions of ligand-dependent differences in ERK signaling (14-
16). Previous studies using immunoblotting showed that etorphine-induced ERK phosphorylation was dependent 
on b-arrestins, whereas morphine activated ERK via a PKC-dependent pathway (15). However, we show that 
upon PKC inhibition, morphine can still induce ERK phosphorylation, although this signal has different 
temporal dynamics and occurs both in the cytosol and the nucleus (Fig. 3 and 7B). Therefore, the activation of 
cytosolic ERK by morphine is not PKC-dependent but rather PKC, by controlling MOPr localization, dictates 
the dynamics and location of this response. It is interesting to consider that in the context of a whole cell 
following solubilization (with a relatively greater contribution of cytosolic compared to nuclear ERK), this 
altered temporal profile could appear as an apparent decrease in morphine stimulated ERK. This illustrates the 
extra mechanistic detail that can be obtained by resolving spatial and temporal signaling dynamics in live cells. 
We therefore propose that plasma membrane organization of MOPr, not just b-arrestin recruitment and 
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internalization, dictates the spatiotemporal outcome of receptor activation. Importantly, these mechanisms 
operate in nociceptive neurons, and may thus contribute to the analgesic actions of opioids. 
 
The ability of DAMGO, but not morphine, to cause receptor redistribution may relate to differential patterns of 
MOPr phosphorylation. While all opioids cause phosphorylation of MOPr at Ser375, this is mediated by 
different kinases depending on the ligand (9, 39). Previous studies have shown that the DAMGO-activated 
MOPr is phosphorylated by GRKs 2 and 3 and that internalizing ligands drive higher-order phosphorylation of 
flanking residues that result in efficient b-arrestin recruitment and receptor internalization (9). Here we show that 
recruitment of b-arrestin-2, MOPr translocation and activation of nuclear ERK in response to DAMGO precede 
receptor internalization. As such, we hypothesize that differential recruitment of regulatory proteins (GRKs, b-
arrestins) to MOPr may underlie receptor redistribution at the plasma membrane, and thus indirectly control 
spatiotemporal signaling. This is supported by the fact that mutation of the key hierarchical phosphorylation site 
of MOPr (MOPr S375A) affects the localization of the receptor within the plasma membrane and its 
spatiotemporal signaling. In this context, b-arrestins are increasingly recognized as scaffolding proteins for 
signaling complexes, in addition to their traditional roles in the regulation of receptor desensitization and 
internalization (40). Furthermore, recent evidence suggests that GRKs can also have important scaffolding 
functions, particularly for the control of ERK activation (41, 42). We hypothesize that differential assembly of 
receptor kinases and other signaling mediators in response to morphine versus DAMGO stimulation of MOPr 
determines receptor redistribution, transient signaling profiles and activation of nuclear ERK. Importantly, this 
entails that the responses of opioid ligands will be highly dependent on the specific protein content of opioid-
responsive cells (6, 7, 43, 44). 
 
Our results also highlight the importance of PKCa in governing MOPr spatiotemporal signaling profiles. 
Previous studies have shown that phosphorylation and desensitization of MOPr following morphine stimulation 
is partially dependent upon PKC (39, 45, 46). Moreover, there are strong indications that PKC plays a significant 
role in the initiation and maintenance of tolerance to morphine analgesia (47, 48). To date, evidence for 
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morphine-induced activation of PKC comes from co-immunoprecipitation studies showing recruitment of over-
expressed PKCe to MOPr (16) and increased PKC activity in cell lysates (49). By measuring endogenous PKC 
activity at the subcellular level, we directly demonstrate that morphine, but not DAMGO, stimulates a sustained 
activation of PKC at the plasma membrane. While PKC can phosphorylate MOPr directly (32, 50), it can also 
phosphorylate proteins that participate in MOPr signaling such as Gai (51) or GRK2 (52) and could therefore 
restrict receptor redistribution by modulating the function and/or association of such signaling and scaffolding 
proteins with MOPr.  
 
It is clear that plasma membrane organization plays a critical role in the control of MOPr spatiotemporal 
signaling. Whether MOPr resides within biochemically-defined lipid-rich plasma membrane regions is 
controversial (53-55). However, and in line with our findings, previous studies have provided evidence for a 
restricted plasma membrane localization, and agonist-regulated plasma membrane diffusion of the MOPr (56-
59). Protein-protein interactions were hypothesized to mediate the restricted and slow diffusion of agonist-
stimulated non-internalizing MOPr (60). Together with the results presented here, this suggests that the dynamic 
organization of MOPr within the plasma membrane, rather than MOPr association with a pre-defined lipid-rich 
domain, may control ligand-dependent receptor redistribution and unique spatiotemporal signaling profiles. The 
dependence of MOPr signaling on plasma membrane localization extends recent studies demonstrating distinct 
control of spatiotemporal signaling by endosomally-localized GPCRs (2, 61). In the context of MOPr, 
mechanistic insight into the actions of morphine at the cellular level is of particular therapeutic relevance due to 
the severe side-effects induced by this opiate. Whether chronic exposure to opiates differentially alters 
spatiotemporal signaling and/or the plasma membrane distribution of MOPr remains to be investigated.  
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Materials and Methods 
Reagents, cDNAs and methods for Supplementary Figures are described in Supplementary Materials and 
Methods. 
 
Cell culture and inhibitors 
HEK293 cells were grown in DMEM supplemented with 5% v/v FBS. Cells were transfected using linear 
polyethyleneimine (PEI) (62). For siRNA, cells were transfected with 25 nM scrambled or combined b-arrestin-
1 and b-arrestin-2 SMARTpool ON-TARGETplus siRNA with Lipofectamine 2000 24 h prior to transfection 
with receptor and biosensors. 
 
Cells were pre-treated with inhibitors for 30 min at 37°C, except for Filipin III, MbCD or MbCD/cholesterol 
complexes (45 min) or PTx (16 hours). MbCD/cholesterol complexes were formed as described previously (63). 
Inhibitors were used at the following concentrations: 30 µM PitStop2 or inactive PitStop2, 10 µM NF023, 100 
ng/mL PTx, 5 µM mSIRK or mSIRK L9A, 1 µM GF109203X or Gö6983, 10 nM Gö6976, 10 µM Myr-
EAVSLKPT-OH (inhibitory PKCe peptide, iPKCe), 1 µg/mL Filipin III, 10 mM MbCD, 2 mM MbCD with 0.2 
mM cholesterol (MbCD/cholesterol complexes). 
 
All experiments were performed in live cells at 37°C. For all regulation and trafficking experiments cells were 
stimulated with an EC50 concentration of DAMGO or morphine (both 1 µM) defined by b-arrestin-2 
concentration-response curves (fig. S2A). For all signaling experiments cells were stimulated with an EC50 
concentration of DAMGO (10 nM) or morphine (100 nM) defined by AlphaScreen pERK assays (fig. S1A). 
 
DRG isolation and culture 
All procedures involving mice were approved by the Monash Institute of Pharmaceutical Sciences animal ethics 
committee. DRG neurons were isolated and nucleofected with 600 ng of cytoEKAR Cerulean/Venus, nucEKAR 
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Cerulean/Venus or pmCKAR using the Nucleofector system (Lonza) (see (62) for detailed protocols of DRG 
isolation and nucleofection).  
 
Bioluminescence Resonance Energy Transfer 
HEK293 cells were transfected with 1 µg MOPr-RLuc and 4 µg KRas-Venus, Rab5a-Venus or b-arrestin-2-
YFP. For co-expression, cells were transfected with an additional 2 µg of bARKct, GFP-dynamin or GFP-
dynamin K44E. After 24 hours cells were plated in poly-D-lysine-coated 96-well plates (CulturPlate, 
PerkinElmer) and allowed to adhere. 48 hours post-transfection, cells were equilibrated in HBSS then stimulated 
with vehicle (0.1% DMSO), DAMGO or morphine for 30 min. Coelenterazine h (Promega) was added at a final 
concentration of 5 µM and cells were incubated for 10 min. BRET measurements were obtained using a 
PHERAstar Omega (BMG Labtech, Germany) that allows sequential integration of the signals detected at 
475±30 and 535±30 nm using filters with the appropriate band pass. Data are presented as a BRET ratio 
(calculated as the ratio of YFP to RLuc signals) corrected for vehicle.  
 
FRET 
HEK293 cells were transfected with 55 ng/well MOPr and 40 ng/well cytoEKAR GFP/RFP, nucEKAR 
GFP/RFP, cytoCKAR or pmCKAR. For co-expression, cells were transfected with an additional 50 ng/well 
bARKct, GFP-dynamin or GFP-dynamin K44E. Experiments co-expressing GFP-dynamin or GFP-dynamin 
K44E used the Cerulean/Venus FRET sensors. FRET was measured using a high-content GE Healthcare INCell 
2000 Analyzer (see (62) for detailed protocols). Briefly, fluorescence imaging was performed using a Nikon 
Plan Fluor ELWD 40x (NA 0.6) objective and FRET module. For GFP/RFP emission ratio analysis, cells were 
sequentially excited using a FITC filter (490/20) with emission measured using dsRed (605/52) and FITC 
(525/36) filters, and a polychroic optimized for the FITC/dsRed filter pair (Quad4). For CFP/YFP or 
Cerulean/Venus emission ratio analysis, cells were sequentially excited using a CFP filter (430/24) with 
emission measured using YFP (535/30) and CFP (470/24) filters, and a polychroic optimized for the CFP/YFP 
filter pair (Quad3). HEK293 cells were imaged every 1 min, allowing image capture of 14 wells per min; DRG 
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neurons were imaged every 1 min with four fields of view per well, allowing capture of 3 wells per min. At the 
end of every experiment, the same cells were stimulated with the positive control (200 nM phorbol 12,13-
dibutyrate for ERK or 200 nM phorbol 12,13-dibutyrate with phosphatase inhibitor cocktail 2 (Sigma Aldrich) 
for PKC) for 10 min to generate a maximal FRET change, and positive emission ratio images were captured for 
4 min. 
 
Data were analyzed using the FIJI distribution of ImageJ (64). The three emission ratio image stacks (baseline, 
stimulated, positive) were collated and aligned using the StackCreator script (62). Cells were selected and 
fluorescence intensity measured over the combined stack. Background intensity was subtracted, then FRET data 
plotted as the change in FRET emission ratio relative to the maximal response for each cell (FRET 
ratio/maximum FRET ratio; F/FMax). For HEK293, only cells that showed more than a 10% change relative to 
baseline following stimulation with the positive control were considered for analysis. For DRG neurons, all cells 
that showed more than a 3% change relative to baseline following stimulation with the positive control were 
considered for analysis. 
  
Ratiometric pseudocolor images were generated according to (65). The Green Fire Blue LUT was applied, and 
the Brightness and Contrast range was set to the minimum and maximum FRET ratios within the image stack 
(0.13-0.23). 
 
GSD/TIRF microscopy 
HEK293 cells and DRG neurons were stimulated with vehicle (0.1% DMSO), DAMGO or morphine as 
indicated, fixed in 4% paraformaldehyde (20 min, 4°C), washed for 15 min with PBS, blocked in PBS with 1% 
Normal goat serum and 0.1% saponin (1 hour, RT), and incubated overnight at 4°C with mouse anti-FLAG 
antibody (1:1000) for HEK293 or rabbit anti-MOPr (UMB-3, 1:250) and anti-tubulin bIII (1:1000) for DRG 
neurons. Cells were washed and incubated with Alexa568- or Alexa647-conjugated goat anti-mouse or anti-
rabbit secondary antibodies (1:400, 2 hours, RT). Coverslips were mounted on a concave slide containing 100 
18 
mM cysteamine (MEA) and sealed. Cells were observed with a Leica GSD microscope with HCX PL APO 160x 
(NA 1.43) objective, SuMo stage, Andor iXon Ultra 897 camera and LAS AF software. Pumping occurred at 
100% laser power until the frame correlation dropped to 0.25. Data were acquired at 50% laser power, and up to 
30,000 frames captured. TIRF penetration was at 110 nm. Only neurons with positive staining for β-tubulin were 
analyzed. Images were analyzed in FIJI (64). Individual particles were selected using Find Maxima (noise 
tolerance 5) to generate a binary output of the single points. The average distance between events was calculated 
by creating a centroid list using the Analyze Particles command, and processed by the Nearest Neighbor 
Distance (NND) macro (Yuxiong Mao). Euclidean distance maps were generated from the single point binary 
image using the Euclidean Distance option.  
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Figure Legends. 
 
Figure 1. Ligand-dependent spatiotemporal signaling of MOPr. A-D, Spatiotemporal activation of ERK 
following vehicle, DAMGO or morphine stimulation. (A) Cytosolic ERK (416-606 cells). (B) Representative 
pseudocolor ratiometric images of cytoEKAR. (C) Nuclear ERK (561-810 cells). (D) Representative 
pseudocolor ratiometric images of nucEKAR. Pseudocolor scale as in B. E-F Spatiotemporal activation of PKC 
following vehicle, DAMGO or morphine stimulation. (E) Plasma membrane-localized PKC (155-220 cells). (F) 
Cytosolic PKC (45-115 cells). Symbols represent means, error bars SEM. 
 
Figure 2. Effect of Gai/o protein inhibition, b-arrestin knockdown or inhibition of endocytosis on cytosolic 
and nuclear ERK activation by MOPr. A-B, MOPr trafficking to early endosomes (n³3) in response to 30 min 
vehicle, DAMGO or morphine in the presence of (A) the clathrin-mediated endocytosis inhibitor PitStop2 (PS2) 
or inactive control, or upon expression of wild-type (WT) dynamin or dominant negative dynamin K44E or (B) 
with and without knockdown of b-arrestins or pre-incubation with Gai/o protein inhibitors. C-F, Spatial activation 
of ERK following vehicle, DAMGO or morphine stimulation, with and without knockdown of b-arrestins, Gai/o 
protein inhibition, in the presence of PS2 or inactive control, or upon expression of WT or K44E dynamin. (C) 
Cytosolic ERK (19-168 cells) with Gai/o protein inhibition or knockdown of b-arrestins. (D) Cytosolic ERK (35-
245 cells) following inhibition of endocytosis. (E) Nuclear ERK (52-258 cells) with Gai/o protein inhibition or 
knockdown of b-arrestins. (F) Nuclear ERK (51-306 cells) following inhibition of endocytosis. Bars/symbols 
represent means, error bars SEM. * p<0.05, ** p<0.01, *** p<0.001 versus vehicle control, two-way ANOVA 
with Tukey’s multiple comparison test. AUC, area under the curve; scram., scrambled; b-arr., b-arrestin; PTx, 
pertussis toxin. 
 
Figure 3. Role of PKC activation by morphine in the spatiotemporal control of ERK activity.  (A) The 
effect of G protein inhibitors or inactive controls on plasma membrane PKC activity following vehicle, DAMGO 
or morphine stimulation (39-229 cells). B-D, MOPr spatiotemporal activation of ERK following vehicle, 
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DAMGO or morphine stimulation with or without inhibition of Gbg or PKC. (B) Cytosolic ERK (31-101 cells). 
(C) Nuclear ERK (74-126 cells). (D) Nuclear ERK analyzed as area under the curve (AUC; 22-360 cells). E-F, 
MOPr trafficking (n³3) following vehicle, DAMGO or morphine stimulation with or without inhibition of Gbg 
or PKC. (E) MOPr-RLuc and Rab5a-Venus BRET. (F) MOPr-RLuc and KRas-Venus BRET. G-I, Effect of 
phosphorylation site mutations on MOPr regulation, trafficking and nuclear ERK. (G) MOPr-RLuc8 and b-
arrestin-2-YFP BRET (n=3-7). (H) MOPr-RLuc8 and Rab5a-Venus BRET (n=3-4). (I) Nuclear ERK (87-359 
cells). Bars/symbols represent means, error bars SEM. * p<0.05, ** p<0.01 and *** p<0.001 versus vehicle 
control, two-way ANOVA with Tukey’s (A,D) or Dunnett’s (E-I) multiple comparison tests. PTx, pertussis 
toxin; GFx, GF109203X; WT, wild-type. 
 
Figure 4. DAMGO induces a unique MOPr distribution at the plasma membrane. Plasma membrane 
distribution of FLAG-MOPr in response to 10 min vehicle, DAMGO or morphine using GSD/TIRF (n=3-9). (A) 
Representative GSD/TIRF images and Euclidean distance maps (EDM) under control conditions. Scale bar 1 
µm. (B) Average distance to nearest neighbor under control conditions. (C) Average distance to nearest neighbor 
following Gbg inhibition. (D) Representative GSD/TIRF images and EDM following Gbg inhibition. Scale bar 1 
µm, pseudocolor scale as in A. (E) Representative GSD/TIRF images and EDM of wild-type MOPr (WT) or 
MOPr S375A under basal conditions. Scale bar 1 µm, pseudocolor scale as in A. (F) Average distance to nearest 
neighbor. Bars represent means, error bars SEM. *** p<0.001 versus vehicle control, one-way ANOVA with 
Dunnett’s multiple comparison test (B,C) or unpaired t-test (E). 
 
Figure 5. Disruption of membrane architecture alters MOPr signaling profiles. Spatiotemporal activation of 
PKC and ERK following vehicle, DAMGO or morphine stimulation, with and without pre-treatment with 
MbCD or MbCD/cholesterol complexes (MbCD/choles.). (A) Plasma membrane-localized PKC in response to 
DAMGO (40-174 cells). (B) Cytosolic ERK in response to DAMGO (30-167 cells). (C) Nuclear ERK in 
response to DAMGO (68-230 cells). (D) Plasma membrane-localized PKC in response to morphine (41-195 
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cells). (E) Cytosolic ERK in response to morphine (32-194 cells). (F) Nuclear ERK in response to morphine (80-
217 cells). Symbols represent means, error bars SEM. 
 
Figure 6. Spatiotemporal signaling of endogenous MOPr in DRG neurons. A-F, Spatiotemporal activation 
of ERK or PKC following vehicle, DAMGO or morphine stimulation. (A) Cytosolic ERK (56-120 neurons). (B) 
Nuclear ERK (45-64 neurons). (C) Plasma membrane-localized PKC (40-55 neurons). (D) Effect of PKC 
inhibition on cytosolic ERK (86-99 neurons). (E) Population analysis of the temporal profile of cytosolic ERK, 
with the number of neurons in each group indicated. (F) Effect of PKC inhibition on nuclear ERK (25-73 
neurons). G-I, Plasma membrane distribution of endogenous MOPr in response to 10 min vehicle, DAMGO or 
morphine using GSD/TIRF (n=9-15). (G) Isolated DRG neuron immunostained for MOPr (green) and tubulin 
bIII (magenta). Scale bar 10 µm. (H) Representative GSD/TIRF images and Euclidean distance maps (EDM). 
Scale bar 1 µm. (I) Average distance to nearest neighbor. Bars/symbols represent means, error bars SEM. * 
p<0.05; ** p<0.01 and *** p<0.001 versus vehicle control, two-way ANOVA with Tukey’s multiple 
comparison test (F) or one-way ANOVA with Dunnett’s multiple comparison test (I). AUC, area under the 
curve. 
 
Figure 7. Plasma membrane localization controls MOPr spatiotemporal signaling. (A) DAMGO causes 
recruitment of GRK2 and b-arrestin-2 (1), facilitating MOPr redistribution across the plasma membrane and 
transient activation of Gai/o-mediated cytosolic ERK and Gai/o-independent nuclear ERK (2). Upon prolonged 
stimulation of MOPr, DAMGO triggers MOPr clustering and receptor internalization via clathrin-coated pits (3) 
to early endosomes (4). (B) Morphine stimulates plasma membrane-localized Gbg-PKCa that prevents receptor 
translocation within the plasma membrane. This causes a sustained activation of Gai/o-mediated cytosolic ERK 
(1). Inhibition of the Gbg-PKCa-pathway, or alteration of plasma membrane organization facilitates MOPr 
translocation and activation of nuclear ERK by morphine (2) without receptor internalization. 







